A newly identified Covid-19 variant known as BA.3.2, informally nicknamed “Cicada,” is drawing the attention of scientists and public health authorities worldwide due to its unusually large number of mutations. First detected in South Africa on November 22, 2024, the Omicron-descendant lineage has now been reported in at least 23 countries, including the United States, where it has appeared in clinical cases, traveller screenings and wastewater samples across 25 states.
Researchers say BA.3.2 carries around 70-75 mutations in the spike protein, raising concerns that it could partially evade immunity from vaccines or prior infection. However, global health agencies including the World Health Organization (WHO) say the variant currently remains rare and has not shown evidence of causing more severe disease or higher hospitalisation rates, though scientists continue to closely monitor its spread and potential public-health impact.
Scientists Monitor Highly Mutated ‘Cicada’ Variant
The BA.3.2 lineage has gained attention primarily because of the sheer number of mutations it carries, particularly in the spike protein, the part of the coronavirus that enables it to enter human cells and the main target of antibodies generated by vaccination or previous infection. Early laboratory analysis suggests that some of these mutations may allow the virus to partially escape immune responses, meaning antibodies could neutralise the virus less effectively.
Experts note that such immune-escape characteristics can potentially influence how easily the virus spreads through populations that already have some immunity. The nickname “Cicada” was informally given by researchers to reflect the possibility that the virus circulated quietly for months before appearing clearly in genomic surveillance systems, similar to cicadas emerging after long periods underground.
Despite these concerns, scientists stress that current Covid-19 vaccines are still expected to provide protection against severe illness, hospitalisation and death. Early patient detections have not shown unusual symptoms compared with earlier Covid-19 variants, and common signs remain fever, cough, fatigue, headache, sore throat and respiratory discomfort.
From South Africa Detection to Global Surveillance
The BA.3.2 lineage is a descendant of BA.3, a branch of the Omicron family that briefly circulated during the early Omicron wave between 2021 and 2022. Scientists believe the variant likely evolved gradually between late 2023 and mid-2024, before being detected in a respiratory sample collected in South Africa in November 2024.
For several months the variant appeared only rarely in genomic databases, suggesting it may have circulated at low levels before being picked up by routine monitoring programmes. Surveillance systems eventually detected it in multiple countries, including Australia, Germany and the United States.
In the United States, the first detection occurred on June 27, 2025, when a traveller arriving from the Netherlands tested positive through the CDC’s traveller-based genomic surveillance programme at San Francisco International Airport.
The first confirmed case in a US patient was reported on January 5, 2026, and by February the variant had been identified in four travellers, five clinical samples, aircraft wastewater and more than 130 wastewater samples across 25 states, indicating the virus may have been circulating before clinical cases were widely identified.
Because of its mutation profile and emerging detections, the World Health Organization designated BA.3.2 as a “Variant Under Monitoring” in December 2025, signalling that it warrants close observation but does not currently pose a higher global health risk compared with other circulating strains.
The Logical Indian’s Perspective
The emergence of BA.3.2 serves as a reminder that the story of Covid-19 is still evolving, even as much of the world has moved beyond the emergency phase of the pandemic. Viruses naturally mutate, and the appearance of new variants is a normal part of their life cycle.
What matters most is how societies respond with science, transparency and collective responsibility rather than fear or misinformation. Continuous surveillance, data sharing and equitable access to vaccines remain vital to ensure that new variants are identified early and managed effectively.
